Literature DB >> 25179431

Expression of the P2Y₂ receptor on the rat ocular surface during a 1-year rearing period.

Hidetoshi Tanioka1, Yumi Kuriki, Asuka Sakamoto, Osamu Katsuta, Kouichi Kawazu, Masatsugu Nakamura.   

Abstract

PURPOSE: P2Y2 receptors are expressed on ocular surface tissues. Diquafosol ophthalmic solution (DIQUAS(®) ophthalmic solution 3 %; Santen Pharmaceutical Co., Ltd.) acts on these receptors and promotes the secretion of water and mucin. It has been shown to be an efficient dry eye treatment. If P2Y2 receptor expression on the ocular surface decreases with age, the effect of diquafosol may be reduced in elderly persons. In this study, we investigated the changes in P2Y2 receptor expression on the rat ocular surface over an extended period of time.
METHODS: P2Y2 receptor expression in the conjunctiva, cornea, meibomian gland and lacrimal glands of male and female Sprague-Dawley rats was examined from 5 weeks until 53 weeks of age using immunostaining and quantitative-PCR.
RESULTS: In the immunohistological examinations, P2Y2 receptor expression was observed in the conjunctival epithelium containing goblet cells, corneal epithelium, meibomian gland ductal epithelium and lacrimal gland ductal epithelium. However, its expression was not significantly different between each age group or between sexes. Regarding P2Y2 receptor mRNA expression, there was an age-related increase in the bulbar conjunctiva. In particular, a significant increase was observed in the 53-week-old age group as compared to the 5-week-old female age group. However, age-related changes in expression were not observed in the cornea or meibomian gland in males or females.
CONCLUSIONS: We observed no significant age-related decrease was observed for P2Y2 receptor protein and mRNA expression on rat ocular surface tissues.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25179431     DOI: 10.1007/s10384-014-0342-4

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  28 in total

Review 1.  Regulation of mucin and fluid secretion by conjunctival epithelial cells.

Authors:  Darlene A Dartt
Journal:  Prog Retin Eye Res       Date:  2002-11       Impact factor: 21.198

2.  Postnatal development of P2 receptors in the murine gastrointestinal tract.

Authors:  Cristina Giaroni; Gillian E Knight; Elena Zanetti; Anna Maria Chiaravalli; Sergio Lecchini; Gianmario Frigo; Geoffrey Burnstock
Journal:  Neuropharmacology       Date:  2006-01-23       Impact factor: 5.250

Review 3.  Receptors for purines and pyrimidines.

Authors:  V Ralevic; G Burnstock
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

4.  Changes in expression of P2 receptors in rat and mouse pancreas during development and ageing.

Authors:  R Coutinho-Silva; M Parsons; T Robson; G Burnstock
Journal:  Cell Tissue Res       Date:  2001-10-10       Impact factor: 5.249

5.  Age-related changes in P2 receptor mRNA of rat cerebral arteries.

Authors:  L Y Miao; J P Tang; D P Esposito; J H Zhang
Journal:  Exp Gerontol       Date:  2001-12       Impact factor: 4.032

6.  Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

Authors:  J Tauber; W F Davitt; J E Bokosky; K K Nichols; B R Yerxa; A E Schaberg; L M LaVange; M C Mills-Wilson; D J Kellerman
Journal:  Cornea       Date:  2004-11       Impact factor: 2.651

Review 7.  Diquafosol tetrasodium: a novel dry eye therapy.

Authors:  Kelly K Nichols; Ben Yerxa; Donald J Kellerman
Journal:  Expert Opin Investig Drugs       Date:  2004-01       Impact factor: 6.206

8.  INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model.

Authors:  Tsutomu Fujihara; Tadahiro Murakami; Takashi Nagano; Masatsugu Nakamura; Katsuhiko Nakata
Journal:  J Ocul Pharmacol Ther       Date:  2002-08       Impact factor: 2.671

9.  Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye.

Authors:  Seika Shimazaki-Den; Hiroyuki Iseda; Murat Dogru; Jun Shimazaki
Journal:  Cornea       Date:  2013-08       Impact factor: 2.651

10.  A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients.

Authors:  Etsuko Takamura; Kazuo Tsubota; Hitoshi Watanabe; Yuichi Ohashi
Journal:  Br J Ophthalmol       Date:  2012-08-21       Impact factor: 4.638

View more
  7 in total

1.  Changes of tear film lipid layer thickness by 3% diquafosol ophthalmic solutions in patients with dry eye syndrome.

Authors:  Dong-Hyun Kang; Yong-Woo Lee; Kyu-Yeon Hwang; Kyung-Min Koh; Young-A Kwon; Byung-Yeop Kim; Sang-Wroul Song; Kook-Young Kim
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

2.  Age Dependent Changes in Corneal Epithelial Cell Signaling.

Authors:  Kristen L Segars; Nicholas A Azzari; Stephanie Gomez; Cody Machen; Celeste B Rich; Vickery Trinkaus-Randall
Journal:  Front Cell Dev Biol       Date:  2022-05-05

3.  Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?

Authors:  Wendy R Kam; Yang Liu; Juan Ding; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-08-01       Impact factor: 4.799

4.  Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study.

Authors:  Shima Fukuoka; Reiko Arita
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

5.  Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction.

Authors:  Shiro Amano; Kenji Inoue
Journal:  Clin Ophthalmol       Date:  2017-09-14

6.  The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study.

Authors:  Yue Guo; Jun Young Ha; He Long Piao; Mi Sun Sung; Sang Woo Park
Journal:  BMC Ophthalmol       Date:  2020-07-10       Impact factor: 2.209

Review 7.  Potential Therapeutic Role of Pituitary Adenylate Cyclase-Activating Polypeptide for Dry Eye Disease.

Authors:  Takahiro Hirabayashi; Junko Shibato; Ai Kimura; Michio Yamashita; Fumiko Takenoya; Seiji Shioda
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.